Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 4/20 | 0.67 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.67 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.67 |
| ▸ | CDK2 | P24941 | 3/20 | 0.67 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.67 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 16/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | GRK5 | P34947 | 1/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239702 | 0.80 | CDK5 (1.00) | CDK9CDK5CCNT1CCNA2CDK2 | |
| SCHEMBL1603523 | 0.79 | PDPK1 (1.00) | CDK9CDK5CCNT1CCNA2CDK2 | |
| SCHEMBL1840300 | 0.73 | CDK9 (0.67) | CDK9CDK5CCNT1CCNA2CDK2 | |
| SCHEMBL14001685 | 0.72 | PDPK1 (0.78) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL20758175 | 0.72 | CDK2 (0.70) | CDK9CDK5CCNT1CCNA2CDK2 | |
| SCHEMBL1840596 | 0.72 | CDK9 (0.72) | CDK9CDK5CCNT1CCNA2CDK2 | |
| SCHEMBL1603418 | 0.72 | PDPK1 (1.00) | CDK9CCNT1CCNA2CDK2PDPK1 | |
| SCHEMBL2238419 | 0.72 | CDK5 (0.69) | CDK9CDK5CCNT1CCNA2CDK2 | |
| SCHEMBL1839300 | 0.71 | CDK9 (0.74) | CDK9CDK5CCNT1CCNA2CDK2 | |
| SCHEMBL1604923 | 0.71 | PDPK1 (1.00) | CDK9CCNT1CCNA2CDK2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155745-B1 | 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives and their use for the treatment of cancers and aids | MERCK PATENT GMBH (DE) | 2015-01-28 | — | — | EP | claimed |
| US-8546390-B2 | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | claimed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | claimed |
| EP-2155745-B1 | 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives and their use for the treatment of cancers and aids | MERCK PATENT GMBH (DE) | 2015-01-28 | — | — | EP | disclosed |
| EP-2155745-B1 | 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives and their use for the treatment of cancers and aids | MERCK PATENT GMBH (DE) | 2015-01-28 | — | — | EP | disclosed |
| US-8546390-B2 | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546390-B2 | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| WO-2008155000-A1 | 6-(PYRROLOPYRIDINYL)-PYRIMIDINE-2-YL-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MKI67, TYMP, TK2 | CDK9 30/4885CDK5 43/4885CCNT1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.